CIPLA Stock Overview
Engages in the manufacture, development, sale, and distribution of pharmaceutical products in India, the United States, South Africa, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 5/6 |
Rewards
Risk Analysis
No risks detected for CIPLA from our risk checks.
Cipla Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,672.50 |
| 52 Week High | ₹1,683.00 |
| 52 Week Low | ₹1,132.00 |
| Beta | 0.36 |
| 11 Month Change | 3.33% |
| 3 Month Change | 12.95% |
| 1 Year Change | 41.00% |
| 33 Year Change | 69.59% |
| 5 Year Change | 299.78% |
| Change since IPO | 51,729.40% |
Recent News & Updates
Cipla (NSE:CIPLA) Is Increasing Its Dividend To ₹13.00
Jun 06
Cipla's (NSE:CIPLA) Upcoming Dividend Will Be Larger Than Last Year's
May 21Recent updates
Cipla (NSE:CIPLA) Is Increasing Its Dividend To ₹13.00
Jun 06Cipla's (NSE:CIPLA) Upcoming Dividend Will Be Larger Than Last Year's
May 21Earnings Update: Cipla Limited (NSE:CIPLA) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts
May 14With EPS Growth And More, Cipla (NSE:CIPLA) Makes An Interesting Case
May 03Is Cipla (NSE:CIPLA) Using Too Much Debt?
Feb 14Do Cipla's (NSE:CIPLA) Earnings Warrant Your Attention?
Jan 26Getting In Cheap On Cipla Limited (NSE:CIPLA) Is Unlikely
Jan 08Is Cipla (NSE:CIPLA) Using Too Much Debt?
Nov 15Do Cipla's (NSE:CIPLA) Earnings Warrant Your Attention?
Oct 05Does Cipla (NSE:CIPLA) Have A Healthy Balance Sheet?
Aug 04Is Cipla (NSE:CIPLA) A Risky Investment?
Mar 24A Look At The Fair Value Of Cipla Limited (NSE:CIPLA)
Mar 06Cipla (NSE:CIPLA) Has A Pretty Healthy Balance Sheet
Dec 11Estimating The Fair Value Of Cipla Limited (NSE:CIPLA)
Aug 19Cipla (NSE:CIPLA) Will Pay A Dividend Of ₹5.00
Jul 30Cipla (NSE:CIPLA) Could Easily Take On More Debt
Jul 14If EPS Growth Is Important To You, Cipla (NSE:CIPLA) Presents An Opportunity
Jul 01Cipla Limited (NSE:CIPLA) Shares Could Be 34% Above Their Intrinsic Value Estimate
Apr 30Do Cipla's (NSE:CIPLA) Earnings Warrant Your Attention?
Mar 23Do Cipla's (NSE:CIPLA) Earnings Warrant Your Attention?
Dec 18Calculating The Fair Value Of Cipla Limited (NSE:CIPLA)
Dec 05Is Cipla (NSE:CIPLA) Using Too Much Debt?
Oct 27If You Like EPS Growth Then Check Out Cipla (NSE:CIPLA) Before It's Too Late
Sep 16Cipla Limited (NSE:CIPLA) Shares Could Be 23% Above Their Intrinsic Value Estimate
Aug 31It's Unlikely That Cipla Limited's (NSE:CIPLA) CEO Will See A Huge Pay Rise This Year
Aug 18Shareholder Returns
| CIPLA | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 2.1% | 1.5% | 1.3% |
| 1Y | 41.0% | 59.4% | 45.4% |
Return vs Industry: CIPLA underperformed the Indian Pharmaceuticals industry which returned 59.4% over the past year.
Return vs Market: CIPLA underperformed the Indian Market which returned 45.4% over the past year.
Price Volatility
| CIPLA volatility | |
|---|---|
| CIPLA Average Weekly Movement | 2.7% |
| Pharmaceuticals Industry Average Movement | 6.2% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.3% |
| 10% least volatile stocks in IN Market | 3.9% |
Stable Share Price: CIPLA has not had significant price volatility in the past 3 months.
Volatility Over Time: CIPLA's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1935 | 27,764 | Umang Vohra | www.cipla.com |
Cipla Limited, together with its subsidiaries, engages in the manufacture, development, sale, and distribution of pharmaceutical products in India, the United States, South Africa, and internationally. The company operates through Pharmaceuticals and New Ventures segments. It offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations for various therapeutic areas, such as MI, angina, heart disease, pulmonary disease, kidney failure, Alzheimer’s disease, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, central nervous system, HIV/AIDS, respiratory, asthma, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women’s health, ophthalmology, and neuro psychiatry.
Cipla Limited Fundamentals Summary
| CIPLA fundamental statistics | |
|---|---|
| Market cap | ₹1.35t |
| Earnings (TTM) | ₹43.03b |
| Revenue (TTM) | ₹258.92b |
31.4x
P/E Ratio5.2x
P/S RatioIs CIPLA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CIPLA income statement (TTM) | |
|---|---|
| Revenue | ₹258.92b |
| Cost of Revenue | ₹90.00b |
| Gross Profit | ₹168.92b |
| Other Expenses | ₹125.89b |
| Earnings | ₹43.03b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 53.29 |
| Gross Margin | 65.24% |
| Net Profit Margin | 16.62% |
| Debt/Equity Ratio | 2.1% |
How did CIPLA perform over the long term?
See historical performance and comparison